Real-world Weight Loss Effectiveness of GLP-1 Agonists in Type 2 Diabetes Patients

Introduction

Markedly elevated body weight is a significant risk factor for major adverse cardiovascular events and all-cause mortality among patients with type 2 diabetes. Achieving and maintaining weight loss in this group can improve glycemic control and reduce the dosage or number of glucose-lowering medications. In some cases, substantial weight loss may result in disease remission.

Methods

The study utilized data from a large integrated healthcare system, focusing on patients with overweight or obesity and type 2 diabetes who started a GLP-1 agonist. The primary outcomes were percent weight change and the proportion of people achieving at least 5% weight loss over 72 weeks.

Results

At 72 weeks, the mean weight loss was 2%, with one-third of the patients achieving at least 5% weight loss. The proportion of patients achieving significant weight loss increased over time, from 11.2% at 8 weeks to 33.3% at 72 weeks.

Discussion

The study's findings suggest that GLP-1 agonists can be effective for weight loss in real-world settings, even without structured behavioral interventions. However, the magnitude of weight loss was less than that observed in clinical trials with structured weight loss interventions. The study underscores the potential added value of combining pharmacologic treatments with structured weight loss interventions for better outcomes.

Limitations

The study's generalizability may be limited due to its focus on a predominantly white population from a single healthcare system. Additionally, the study did not examine the effects of higher dosages of GLP-1 agonists or the impact of high medication adherence on weight loss.

Conclusion

GLP-1 agonists may offer a viable option for weight loss in patients with type 2 diabetes and overweight or obesity in real-world settings. Future research should explore the effects of full adherence to GLP-1 agonist therapy and identify factors associated with less observed weight loss in real-world patients.